Make Sure Patients on Sublocade Have an Active Order in the EHR

March 2018

Sublocade (SUB-loh-kayd) will be the first monthly buprenorphine injection for patients with opioid use disorder.

It's a subcutaneous depot injection given in the abdomen for patients stable on 8 to 24 mg/day of buccal or sublingual buprenorphine.

But it's different from Probuphine, the 6-month implant that's only for patients on up to 8 mg/day of buprenorphine.

Get unlimited access through an Enterprise license

Hospital Pharmacist's Letter includes:

12 issues every year, with brief articles about new meds and hot topics
300+ CE courses, including the popular CE-in-the-Letter
Quick reference drug comparison charts
Access to the entire archive

Learn More

Already a subscriber? Log in

Not sold to individuals

Table of Contents

Shortages Assess Alternatives When Sterile Water Runs Dry
Substance Use Disorder Be Prepared to Treat Alcohol Withdrawal Patients Refractory to Benzodiazepines
Nausea Vomiting Consider the Benefits of New Meds to Prevent Chemo-Induced Nausea and Vomiting
New Drugs Don't Expect the New Anticoagulant Betrixaban to be Added to Your Formulary
Hyperglycemia Don't Jump to Insulin in All Patients With Steroid-Induced Hyperglycemia
Obesity Weight Loss Help With Med Adjustments After Weight Loss Surgery
New Drugs Make Sure Patients on Sublocade Have an Active Order in the EHR
Bowel Preps Help Reduce Cancelled Colonoscopies by Minimizing Inadequate Bowel Preps
Pregnancy Weigh Pros and Cons of Antibiotic Options for UTI in Pregnancy
Poison Prevention Help Protect Patients From Accidental Poisonings
New Drugs Don't Expect the New Anticoagulant Betrixaban to be Added to Your Formulary
New Drugs Make Sure Patients on Sublocade Have an Active Order in the EHR